Phase I/II study of a combined gemcitabine, etoposide, and cisplatin chemotherapy regimen for metastatic urothelial carcinoma

Cancer

Volumn 106, Issue 11, 2006, Pages 2363-2368

  Tsukamoto, Tetsuro ^a,b   Yonese, Junji ^a   Ohkubo, Yuhei ^a   Fukui, Iwao ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b Showa General Hospital   (Japan)

Author keywords

Cisplatin; Etoposide; Gemcitabine; Phase I II study; Urothelial carcinoma

Indexed keywords

CISPLATIN; CORTICOSTEROID; GEMCITABINE;

ADULT; AGE; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION; LYMPH NODE METASTASIS; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SEPSIS; STOMATITIS; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; UROGENITAL TRACT CANCER;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE; UROLOGIC NEOPLASMS;

EID: 33646892392     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21897     Document Type: Article

References (17)

1. Logothetis C, Dexeus F, Finn L, et al. A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumor. J Clin Oncol. 1990;8:1050-1055.
2. Saxman SB, Propert KI, Einhorn LH, et al. Long-term follow-up of a Phase I/II intergroup study of cisplatin alone or in combination with methotrexate, vinblastin, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564-2569.
3. Fukui I, Yonese J, Tsukamoto T, et al. Combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin for metastatic urothelial cancer. Cancer Chemother Pharmacol. 2001;48:88-93.
4. Pollera CF, Ceribelli A, Crecco M, et al. Weekly gemcitabine in advanced bladder cancer: a preliminary report from Phase I study. Ann Oncol. 1994;5:182-184.
5. DeLena M, Gridelli C, Lorusso V, et al. Gemcitabine activity (objective responses and symptom improvement) in resistant Stage IV bladder cancer [abstract]. Proc Am Soc Clin Oncol. 1996;15:246.
6. Stadler WM, Kuzel TM, Roth B, et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997;15:3394-3398.
7. Moore MJ, Tannock IF, Ernst DS, et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 1997;15:3441-3445.
8. Kaufman D, Stadler W, Carducci M, et al. Gemcitabine (GEM) plus cisplatin (CDDP) in metastatic transitional cell carcinoma (TCC): final results of a Phase II study [abstract]. Proc Am Soc Clin Oncol. 1998;17:320a.
9. Moore MJ, Tannock IF, Winquist E, et al. Gemcitabine (G) + cisplatin (C): an active regimen in advanced transitional cell carcinoma (TCC) [abstract]. Proc Am Soc Clin Oncol. 1998;17:320a.
10. Von der Masse H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastin, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J Clin Oncol. 2000;17:3068-3077.
11. Walther PJ, Williams SD, Troner M, Greco FA, Birch R, Einhorn LH. Phase 2 study of etoposide for carcinoma of the bladder: the Southeastern Cancer Study Group experience. Cancer Treat Rep. 1986;70:1337.
12. Schabel FM, Trader MW, Laster WR, Corbett TH, Griswold DP. Cis-dichlorodiammineplatinum (II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep. 1979;63:1459.
13. Storer BE. Design and analysis of Phase I clinical trials. Biometrics. 1989;45:925-937.
14. Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol. 1993;11:598-606.
15. Tsukamoto T, Yonese J, Ishii N, Maezawa T, Fukui I. Successful salvage chemotherapy with gemcitabine, etoposide and cisplatin for metastatic ureteral cancer: a case report. Acta Urol Jpn. 2002;48:427-430.
16. Tadokoro M, Yonese J, Tsukamoto T, et al. Successful treatment of chemo-refractory pulmonary metastases of renal pelvic cancer by second-line chemotherapy including gemcitabine followed by salvage surgery. Int J Urol. 2005;12:208-210.
17. Siefker-Radtke AO, Walsh GL, Pisters LL, et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol. 2004;171:145-148.